Your session is about to expire
What is Ibandronate Sodium
IbandronateThe Generic name of this drug
Treatment SummaryIbandronate (also known as BM 21.0955) is a type of drug commonly used to help prevent and treat osteoporosis in postmenopausal women. It was first developed in 1993 as a treatment for bone loss in dogs and was approved by the FDA in 2003. Ibandronate is a third-generation bisphosphonate, which is similar to other drugs such as zoledronic acid, minodronic acid, and risedronic acid.
Bonivais the brand name
Ibandronate Sodium Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Boniva
Ibandronate
2005
24
Approved as Treatment by the FDA
Ibandronate, otherwise known as Boniva, is approved by the FDA for 1 uses which include Osteoporosis .Osteoporosis
Helps manage Osteoporosis
Effectiveness
How Ibandronate Sodium Affects PatientsIbandronate is a drug used to both treat and prevent weak bones in postmenopausal women. It is generally considered safe, with effects lasting up to 157 hours. However, it can have some side effects, including upper gastrointestinal problems, low calcium levels, muscle pain, jawbone death, unusual fractures of the thigh bone, and serious issues with the kidneys.
How Ibandronate Sodium works in the bodyBisphosphonates are taken into the bone and bind to hydroxyapatite. This helps to stop osteoclasts from breaking down the bone. Ibandronate, a nitrogen-based bisphosphonate, stops tumor cells from reproducing by blocking certain molecules from the mevalonate pathway. This stops GTP-binding proteins like Rap1 from functioning, resulting in cell death. Ibandronate also activates caspase-3, which also contributes to cell death.
When to interrupt dosage
The proposed measure of Ibandronate Sodium is contingent upon the determined circumstance, for example Bone Metastases, Malignant Neoplasms and Osteoporosis. Dosage additionally depends on the mode of delivery, as demonstrated in the table below.Condition
Dosage
Administration
Osteoporosis
, 3.0 mg/mL, 150.0 mg, 1.0 mg, 3.0 mg, 50.0 mg, 2.0 mg, 6.0 mg, 2.5 mg, 1.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous
Malignant Neoplasms
, 3.0 mg/mL, 150.0 mg, 1.0 mg, 3.0 mg, 50.0 mg, 2.0 mg, 6.0 mg, 2.5 mg, 1.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous
Bone Metastases
, 3.0 mg/mL, 150.0 mg, 1.0 mg, 3.0 mg, 50.0 mg, 2.0 mg, 6.0 mg, 2.5 mg, 1.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous
Breast Cancer
, 3.0 mg/mL, 150.0 mg, 1.0 mg, 3.0 mg, 50.0 mg, 2.0 mg, 6.0 mg, 2.5 mg, 1.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous
Warnings
Ibandronate Sodium ContraindicationsCondition
Risk Level
Notes
Esophageal Strictures
Do Not Combine
Hypocalcemia
Do Not Combine
Esophagus
Do Not Combine
Achalasia, Esophageal
Do Not Combine
Inability to sit or stand upright for at least 60 minutes
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Ibandronate may interact with Pulse Frequency
Common Ibandronate Sodium Drug Interactions
Drug Name
Risk Level
Description
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Hydroxyzine.
Mobocertinib
Major
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mobocertinib.
Ziprasidone
Major
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ziprasidone.
Abexinostat
Minor
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Abexinostat.
Aceprometazine
Minor
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aceprometazine.
Ibandronate Sodium Toxicity & Overdose RiskThose who take too much ibandronate may experience low calcium or phosphate levels, upset stomach, heartburn, esophagitis, and ulcers. To reduce absorption, patients can be given milk or antacids. Intravenous electrolytes may also be administered to help manage the overdose and dialysis is not expected to help remove the drug from the blood.
Ibandronate Sodium Novel Uses: Which Conditions Have a Clinical Trial Featuring Ibandronate Sodium?
729 active trials are currently underway to assess the potential of Ibandronate Sodium to manage Bone Metastases, Malignant Neoplasms and Osteoporosis.Condition
Clinical Trials
Trial Phases
Malignant Neoplasms
0 Actively Recruiting
Osteoporosis
39 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4, Phase 3
Breast Cancer
713 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Bone Metastases
8 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 3
Ibandronate Sodium Reviews: What are patients saying about Ibandronate Sodium?
3Patient Review
10/3/2015 I'm waiting for a test to see the efficacy of this treatment, which won't be until next year.
2.3Patient Review
5/2/2013 I unfortunately experience a red rash as a side effect of this medication. It's most visible behind my knees and inner thighs, but I have also noticed it on my calves and outer thighs. The rash doesn't itch, but it is very unsightly. Usually the rash goes away after a few days; however, I am considering discontinuing the medication because of this issue.
2Patient Review
5/3/2017 I had pain in my hip, thigh, and shoulder 2-3 days after taking the pill. I also felt really tired and achy. The second month I had the same side effects plus indigestion. I hope I don't have to keep dealing with this every month.
1.7Patient Review
7/11/2016 I had such intense and debilitating side effects from this treatment that I would rather take my chances with bone loss than use it again.
1Patient Review
7/5/2016 I started taking this medicine on 7/2/16 and immediately began feeling flu-like symptoms. My arms and legs felt heavy and rubbery, and I was exhausted all the time. I was previously taking Fosamax, which had left me crippled, so I thought I would try this new medication. Unfortunately, it seems to be just as bad, if not worse.
Patient Q&A Section about ibandronate sodium
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is the drug ibandronate sodium used for?
"Ibandronate is a medication used to treat and prevent osteoporosis in postmenopausal women. A prescription is required in order to obtain this medication."
Answered by AI
What are the side effects of ibandronate sodium?
"The symptoms of this illness include nausea, stomach pain, diarrhea, constipation, weakness, dizziness, headache, fever, sore throat, chills, cough, and other signs of infection."
Answered by AI
When should you take ibandronate sodium?
"Adults should take 2.5mg once a day in the morning, or 150mg once a month on the same date, at least 60 minutes before the first food or drink of the day (apart from water). Children's doses must be determined by a doctor."
Answered by AI
How long should you take ibandronate sodium?
"After taking bisphosphonates for at least 3 to 5 years, your doctor will consider your risk factors in determining whether you should continue to take these or other osteoporosis medications."
Answered by AI